Company Profile

Industry Sector: Medical Device

Company Overview:
ARTANN Laboratories, Inc. (Artann) is an innovative technology company with the mission of early stage development and validation of original technologies and devices. The value of Artann's research has been recognized by the support of the Small Business Innovation Research (SBIR) grants from various federal agencies. A unique feature of Artann is a wide scope of its activities. Addressing solicitations from different federal agencies, Artann developed numerous technologies in the diverse fields of medical diagnostics, biosensors and biotechnology, nondestructive testing, various technologies for industrial, aerospace and military applications. Artann has built a solid intellectual property foundation for its technologies with 41 issued and pending US patents. Further, the company has established a sound record of bringing new technologies from the level of an academic idea into the stage of functional prototypes ready for commercialization. To date, Artann licensed five proprietary technologies to private and public companies to carry out the commercialization of its products.

Target Market(s): Clinical, research, medical device

Key Value Drivers

Technology*: Colonoscopy Force Monitor™ (CFM) is a handheld force-measuring attachment mounted on the colonoscope shaft that provides a physician with a real-time feedback on the force and torque applied during colonoscopy. The CFM is designed to improve training of endoscopists and establish best practices for performing colonoscopy by quantitative characterization of expert skill.

Competitive Advantage: Colonoscopy Force Monitor occupies a unique niche in the market for colonoscopy training and QA reporting systems. As we collaborate with developers of computer assisted diagnosis for endoscopy, we are mindful that CFM is a stand alone technology and fits with multiple scenarios in the OEM, training and QA segments.

Plan & Strategy: Seeking private equity and/or strategic partner.

*Technology funded by the NIDDK/NIH and being commercialized under the NIH-CAP

Product Pipeline

ON THE MARKET
- SureTouch™ Tactile Imager for breast cancer screening
- TissueElastometer™
- Tissue Mimicking Phantoms

IN DEVELOPMENT
- Prostate Mechanical Imager ProUroScan™ – FDA approved
- Vaginal Tactile Imager VTI™ - FDA validation study
- Shear Wave Elasticity Imaging Aixplore™ - FDA validation study
- Bone Ultrasonometry – FDA validation study
- Colonoscope Force Monitor – FDA validation study
- Skin Elasticity Analyzer – clinical verification
- Muscle Water Content Monitor – clinical verification
- Droplet Micro-Chromatography – clinical verification
- Endotracheal Tube Monitor – clinical verification

Management

Leadership:
Dr. Noune Sarvazyan (PhD, MBA), CEO of Artann, experienced entrepreneur with a track record of successful technologies commercialization
Dr. Armen Sarvazyan (PhD, DSc), CSO of Artann, Adjunct Professor of Surgery UMDNJ, inventor, pioneer of medical ultrasound
Dr. Vladimir Egorov (PhD), VP Technology Development of Artann, extensive experience in biomedical instrumentation design and development
Dr. Louis Korman (MD), Clinical Principal Investigator, Professor, practicing clinician, leading scientist and educator in GI and metabolic diseases

Contact: Noune Sarvazyan, PhD, MBA
Location: Trenton, NJ, USA
Email: artann@artannlabs.com
Tel: 512-996-8565
Website: www.artannlabs.com